2026 may be a pivotal year for obesity. GLP-1 receptor agonists have revolutionized the management of obesity over the past 10 years. Growing evidence has demonstrated their benefit in many cardiometabolic and obesity-related conditions. More than a billion people live with obesity, with the burden increasing rapidly in low- and middle-income countries. The global weight loss drug market is projected to reach $150 billion by 2035. High costs, limited manufacturing capacity, and supply chain constraints lead to persistent inequitable access to GLP-1 receptor agonists.